



thor medical

Thor Medical ASA – Nomination committee recommendation to the Annual General Meeting

10.4.2026 09:51:00 CEST | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

9 April 2026 | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

The nomination committee has made its recommendation to the Annual General Meeting of Thor Medical ASA that will be held on 23 April 2026, at 14:00 hours CEST at Advokatfirmaet Selmer, Ruseløkkveien 14, 0251 Oslo. The recommendation and the previously distributed notice are not fully aligned, and the company wishes to clarify that the proposed resolutions for the general meeting are as set out in the nomination committee's recommendation with respect to the matters it concerns.

The recommendation of the nomination committee is attached and is also available on www.thormedical.com.

For further information please contact:

Mathias Nilsen Reierth

Head of Communications and Corporate Affairs

Tel: +47 988 05 724

mathias.reierth@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.com

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the Securities Trading Act.

Attachments

- [Download announcement as PDF.pdf](#)
- [Thor Medical - Nomination Committee proposal 2026.pdf](#)